CA2941066C - Anti-ox40l antibodies, uses & methods - Google Patents

Anti-ox40l antibodies, uses & methods Download PDF

Info

Publication number
CA2941066C
CA2941066C CA2941066A CA2941066A CA2941066C CA 2941066 C CA2941066 C CA 2941066C CA 2941066 A CA2941066 A CA 2941066A CA 2941066 A CA2941066 A CA 2941066A CA 2941066 C CA2941066 C CA 2941066C
Authority
CA
Canada
Prior art keywords
antibody
antibodies
seq
sequence
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2941066A
Other languages
English (en)
French (fr)
Other versions
CA2941066A1 (en
Inventor
Jamie Campbell
Steve Holmes
Ian Kirby
Miha Kosmac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of CA2941066A1 publication Critical patent/CA2941066A1/en
Application granted granted Critical
Publication of CA2941066C publication Critical patent/CA2941066C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2941066A 2014-03-04 2015-03-03 Anti-ox40l antibodies, uses & methods Active CA2941066C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201403775A GB201403775D0 (en) 2014-03-04 2014-03-04 Antibodies, uses & methods
GB1403775.8 2014-03-04
PCT/GB2015/050614 WO2015132580A1 (en) 2014-03-04 2015-03-03 Antibodies, uses & methods

Publications (2)

Publication Number Publication Date
CA2941066A1 CA2941066A1 (en) 2015-09-11
CA2941066C true CA2941066C (en) 2023-10-17

Family

ID=50490750

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2941066A Active CA2941066C (en) 2014-03-04 2015-03-03 Anti-ox40l antibodies, uses & methods

Country Status (21)

Country Link
US (9) US10669342B2 (cg-RX-API-DMAC7.html)
EP (2) EP3113797B1 (cg-RX-API-DMAC7.html)
JP (4) JP6795398B2 (cg-RX-API-DMAC7.html)
CN (2) CN106459196B (cg-RX-API-DMAC7.html)
AU (4) AU2015225926B2 (cg-RX-API-DMAC7.html)
CA (1) CA2941066C (cg-RX-API-DMAC7.html)
DE (1) DE112015001085T5 (cg-RX-API-DMAC7.html)
DK (1) DK3113797T3 (cg-RX-API-DMAC7.html)
ES (1) ES2922734T3 (cg-RX-API-DMAC7.html)
GB (1) GB201403775D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20220891T1 (cg-RX-API-DMAC7.html)
HU (1) HUE059338T2 (cg-RX-API-DMAC7.html)
IL (3) IL247582B2 (cg-RX-API-DMAC7.html)
LT (1) LT3113797T (cg-RX-API-DMAC7.html)
NZ (1) NZ723858A (cg-RX-API-DMAC7.html)
PL (1) PL3113797T3 (cg-RX-API-DMAC7.html)
PT (1) PT3113797T (cg-RX-API-DMAC7.html)
RS (1) RS63408B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201607030PA (cg-RX-API-DMAC7.html)
SI (1) SI3113797T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015132580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
LT3265123T (lt) * 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
US9897378B2 (en) 2015-10-08 2018-02-20 Nyc Designed Inspirations Llc Cosmetic makeup sponge/blender container
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CA3032897A1 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN109843182A (zh) * 2016-08-18 2019-06-04 普罗根尼蒂公司 使用可摄入装置获取样品的系统
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019173780A2 (en) * 2018-03-08 2019-09-12 Magenta Therapeutics, Inc. Anti-cd252 antibodies, conjugates, and methods of use
WO2019175224A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
US20220010019A1 (en) * 2018-11-27 2022-01-13 The General Hospital Corporation Targeting intraepithelial lymphocytes for treatment of metabolic syndrome
IL293554A (en) * 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising an immunoglobulin with one variable domain that target tnfa and ox40l
CN111529753A (zh) * 2020-04-28 2020-08-14 宁夏医科大学总医院 氧化苦参碱-胎盘间充质干细胞水凝胶、制备方法及应用
WO2022060798A1 (en) * 2020-09-15 2022-03-24 10X Genomics, Inc. Methods of releasing an extended capture probe from a substrate and uses of the same
JP7688150B2 (ja) * 2020-12-09 2025-06-03 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
CN112852743B (zh) * 2021-01-25 2021-11-02 江苏荃信生物医药有限公司 用于生产乌司奴单抗的生物类似药的细胞株及生产方法
WO2023001987A2 (en) 2021-07-22 2023-01-26 University Of Dundee Therapeutic muteins
AU2022326849A1 (en) * 2021-08-10 2024-03-21 Kymab Limited Treatment of atopic dermatitis
TW202506179A (zh) 2023-04-14 2025-02-16 英商凱麥博有限公司 含有抗ox40l抗體之醫藥配製物
WO2025099280A1 (en) 2023-11-08 2025-05-15 Oxion Biologics Ab Improved anti-ox40l antibodies
WO2025233445A1 (en) 2024-05-08 2025-11-13 Kymab Limited Treatment of head and neck atopic dermatitis

Family Cites Families (598)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4663281A (en) 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
ATE228566T1 (de) 1989-09-20 2002-12-15 Abbott Lab Verfahren zur herstellung von fusionsproteinen
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991013166A1 (en) 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
CA2095842A1 (en) 1990-11-09 1992-05-10 Stephen D. Gillies Bridging antibody fusion constructs
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
HUT74451A (en) 1993-07-15 1996-12-30 Cancer Res Campaign Tech Prodrugs of protein tyrosine kinase inhibitors, systems contg. them and process for preparing them
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5618709A (en) 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DK0805628T3 (da) 1995-01-17 2003-07-14 Brigham & Womens Hospital Receptor specifik transepitheltransport af immunogener
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5998596A (en) 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996038176A1 (fr) 1995-06-01 1996-12-05 Kishimoto, Tadamitsu Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1)
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9610745A (pt) 1995-12-08 1999-07-13 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il) metil-2-quinolinona inibindo a transferase da proteina farnesil
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1997027854A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
EP0907649A1 (en) 1996-06-27 1999-04-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
NL1003648C2 (nl) 1996-07-19 1998-01-21 Carino Cornelis Sunderman Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
EP0928203B1 (en) 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2001509156A (ja) 1997-01-29 2001-07-10 ゼネカ・リミテッド ファルネシルプロテイントランスフェラーゼの阻害剤
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US20060223088A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US7968689B2 (en) 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20060246483A1 (en) 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US20070055056A1 (en) 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US20060223090A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US20080103090A1 (en) 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20070015696A1 (en) 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
SK180299A3 (en) 1997-06-20 2000-06-12 Biogen Inc Cd40:cd154 blockade therapy for pancreatic islet tissue transplantation
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ATE208210T1 (de) 1997-08-15 2001-11-15 Cephalon Inc Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
EP1017723B1 (de) 1997-09-23 2007-01-10 Bundesrepublik Deutschland letztvertreten durch Den Direktor des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU9452998A (en) 1997-10-22 1999-05-10 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
ATE205195T1 (de) 1997-10-22 2001-09-15 Astrazeneca Ab Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
JP4395200B2 (ja) 1997-10-28 2010-01-06 バンドー化学株式会社 皮膚貼付薬シート及びそのための基材シートの製造方法
DE69839060T2 (de) 1997-11-03 2009-01-15 Human Genome Sciences, Inc. Vegi, ein inhibitor der angiogenese und des tumorwachstums
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
EP1045846B1 (en) 1997-11-28 2003-05-02 Lg Chemical Limited Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
PT1058683E (pt) 1998-02-02 2003-04-30 Lg Chemical Ltd Inibidores da farnesil-transferase com uma estrutura de piperidina e seu processo de preparacao
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
WO1999048927A1 (en) 1998-03-25 1999-09-30 Cornell Research Foundation, Inc. Methods for designing specific ion channel blockers
CZ20003767A3 (cs) 1998-04-15 2002-01-16 Lexigen Pharmaceuticals Corp. Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva
BR9909677A (pt) 1998-04-17 2000-12-19 Lexigen Pharm Corp Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas
DK1076663T3 (da) 1998-04-27 2004-06-01 Warner Lambert Co Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
CZ302303B6 (cs) 1998-08-25 2011-02-16 Merck Patent Gmbh Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (fr) 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
HUP0105090A2 (hu) 1999-01-07 2002-04-29 Lexigen Pharmaceuticals Corporation Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
HUP0105044A3 (en) 1999-01-15 2004-07-28 Biogen Inc Cambridge Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
ES2313883T3 (es) 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9907965D0 (en) 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
US20030119038A1 (en) 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20100291099A1 (en) 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
WO2001031007A2 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20020081679A1 (en) 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
PT1233987E (pt) 1999-11-29 2009-12-28 Bac Ip B V Imobilização de moléculas de ligação ao antigénio de um domínio
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
EP1294401B1 (en) 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
CN1203857C (zh) 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
WO2002026210A2 (en) 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002227280A1 (en) 2000-12-08 2002-06-18 Incyte Genomics, Inc. Protein modification and maintenance molecules
CN1630720A (zh) 2001-01-18 2005-06-22 默克专利有限公司 具有葡糖脑苷脂酶活性的双功能融合蛋白
HUP0303171A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
CN1330664C (zh) 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
EP1390390A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US20040023243A1 (en) 2001-06-13 2004-02-05 Yue Henry Proteases
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
US20040038242A1 (en) 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
EP1476180A4 (en) 2001-08-13 2005-04-20 Univ Southern California MUTANTS OF INTERLEUKIN-2 WITH REDUCED TOXICITY
EP1441759A2 (de) 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Zelluläre impfstoffe mit adjuvanzien
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002365814A1 (en) 2001-12-18 2003-07-30 J And J Research Pty Ltd Method of treating asthma
US20060093771A1 (en) 2002-02-15 2006-05-04 Frantisek Rypacek Polymer coating for medical devices
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
MXPA05006384A (es) 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
US7456264B2 (en) 2003-05-21 2008-11-25 Medarex, Inc. Human monoclonal antibodies against Bacillus anthracis protective antigen
US20070041972A1 (en) 2003-05-30 2007-02-22 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1631317A2 (en) 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
JP2007527242A (ja) 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
US7998481B2 (en) 2004-04-05 2011-08-16 The Regents Of The University Of California Modulation of NKG2D for treating or preventing solid organ allograft rejection
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
JP2008501638A (ja) 2004-04-23 2008-01-24 ドイツ連邦共和国 ＩＣＯＳ陽性細胞のｉｎｖｉｖｏ枯渇によるＴ細胞介在病態の治療方法
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
EP1768695A4 (en) 2004-06-29 2008-07-30 Univ Johns Hopkins IMPROVEMENT OF MEDICINE-INDUCED TOXICITY
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN101023102B (zh) 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
KR20070107703A (ko) 2005-02-14 2007-11-07 와이어쓰 인터루킨-１７ｆ 항체 및 기타 ｉｌ-１７ｆ 신호전달안타고니스트 및 그의 용도
US7981605B2 (en) 2005-02-24 2011-07-19 Amgen Inc. Epidermal growth factor receptor mutations
US7351411B2 (en) 2005-03-11 2008-04-01 Regeneron Pharmaceuticals, Inc. Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
KR20080033390A (ko) 2005-08-12 2008-04-16 리제네론 파라마큐티칼스 인코포레이티드 Ｖｅｇｆ 길항제로 질병을 치료하는 방법
GB0517487D0 (en) 2005-08-26 2005-10-05 Isis Innovation Antibodies
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
RU2426744C2 (ru) 2005-12-16 2011-08-20 Дженентек, Инк. Антитела к ox40l и способы их применения
SI1969007T1 (sl) 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
CA2900402C (en) 2006-05-08 2018-01-16 Adaerata, Limited Partnership Pcsk9 polypeptide, ligand to said polypeptide, kits and methods using said ligands
EA015676B1 (ru) 2006-05-11 2011-10-31 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии гена pcsk9
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2038417A2 (en) 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
TWI405771B (zh) 2006-08-28 2013-08-21 Kyowa Hakko Kirin Co Ltd 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US20100068194A1 (en) 2006-10-24 2010-03-18 Dong-Ku Kim Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
NZ596237A (en) 2006-12-27 2012-07-27 Dana Farber Cancer Inst Inc Compositions and methods for the treatment of infections and tumors
AR064826A1 (es) 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
MX2009009194A (es) 2007-02-27 2009-10-08 Genentech Inc Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
CA2681428A1 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
EA019595B1 (ru) 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
RU2549701C2 (ru) 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
US8084656B2 (en) 2007-10-09 2011-12-27 Rentech, Inc. Systems and methods for oxidation of synthesis gas tar
SG2013014352A (en) 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US9176122B2 (en) 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
KR101855381B1 (ko) 2008-04-09 2018-05-09 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
WO2009131740A2 (en) 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
KR20140019035A (ko) * 2008-09-19 2014-02-13 에프. 호프만-라 로슈 아게 신규한 항체 제형
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
ES2719496T3 (es) 2008-11-12 2019-07-10 Medimmune Llc Formulación de anticuerpo
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5542152B2 (ja) 2008-12-23 2014-07-09 コーニンクレッカ フィリップス エヌ ヴェ 身体結合通信及びラジオ周波数通信の組み合わせ
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
SG173620A1 (en) 2009-02-17 2011-09-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
EP2517556B2 (en) 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
AU2010285071A1 (en) 2009-08-17 2012-02-02 Roche Glycart Ag Targeted immunoconjugates
EP2473186A4 (en) 2009-08-31 2013-07-10 Ibc Pharmaceuticals Inc BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
EP2480576A4 (en) 2009-09-25 2013-04-10 Merck Sharp & Dohme PCSK9 ANTAGONISTS
JP5960597B2 (ja) 2009-09-30 2016-08-02 メモリアル スローン−ケタリング キャンサー センター 癌治療のための併用免疫療法
EP2493926B1 (en) 2009-10-27 2020-03-11 UCB Biopharma SRL Function modifying nav 1.7 antibodies
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
EP2494355A4 (en) 2009-10-30 2013-05-01 Merck Sharp & Dohme PCSK9 IMMUNOASSAY
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
EP2493505A4 (en) 2009-10-30 2013-06-12 Merck Sharp & Dohme Ax1 and ax189 pcsk9 antagonists and variants
US20120208208A1 (en) 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
AU2010328347B2 (en) 2009-12-07 2015-12-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for enhancing anti-tumor antibody therapy
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US9133436B2 (en) 2010-02-04 2015-09-15 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
ES2689875T3 (es) 2010-04-13 2018-11-16 Bristol-Myers Squibb Company Proteínas con un dominio de armazón a base de fibronectina que se unen a PCSK9
US20140161794A1 (en) 2010-04-16 2014-06-12 Biogen Idec Ma Inc. Anti-vla-4 antibodies
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
SG186238A1 (en) 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
PH12013500354B1 (en) 2010-08-23 2018-10-19 Univ Texas Anti-ox40 antibodies and methods of using the same
JP5813114B2 (ja) * 2010-08-25 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｌ−１８ｒ１に対する抗体およびその使用
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
EP2665822A1 (en) 2011-01-18 2013-11-27 Amgen Inc. Nav1.7 knockout mice and uses thereof
WO2012101252A2 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
EP2481758A1 (en) 2011-01-28 2012-08-01 Sanofi Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
PE20181077A1 (es) 2011-02-10 2018-07-05 Roche Glycart Ag Polipeptidos interleuquina-2-mutantes
EA201391157A1 (ru) 2011-02-11 2014-02-28 АйАрЭм ЭлЭлСи Антагонисты pcsk9
WO2012132067A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
DK2683406T3 (da) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anti-cd40-antistoffer og anvendelser deraf
CA3050674C (en) 2011-03-31 2021-10-12 Julien FAGET Antibodies directed against icos and uses thereof
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9732196B2 (en) 2011-05-10 2017-08-15 Sabic Global Technologies B.V. Adhesive for bonding polyimide resins
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
EP2720719A4 (en) 2011-06-15 2015-12-09 Glaxosmithkline Ip No 2 Ltd METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
BR112013032667A2 (pt) 2011-06-20 2017-12-12 Genentech Inc polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
MX353931B (es) 2011-07-11 2018-02-02 Glenmark Pharmaceuticals Sa Anticuerpos que se unen a ox40 y sus usos.
CA2840482C (en) 2011-07-14 2018-10-16 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US10634589B2 (en) * 2011-10-26 2020-04-28 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US20130115171A1 (en) 2011-11-09 2013-05-09 Stefan I. McDonough Nav1.7-related assays
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
US20130315913A1 (en) 2012-03-26 2013-11-28 Sanofi Anti-light antibody therapy for inflammatory bowel disease
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2013172933A1 (en) 2012-05-15 2013-11-21 University Of Southern California Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
EP2849788B1 (en) 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
ES2856272T3 (es) * 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
KR102163408B1 (ko) 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CN104363919A (zh) 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
MY175687A (en) 2012-08-07 2020-07-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
KR102207767B1 (ko) 2012-09-17 2021-01-26 갈렉틴 테라퓨틱스, 인크. 암 치료에서의 특이적 면역요법을 강화하는 방법
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
HUE043903T2 (hu) 2012-12-03 2019-09-30 Bristol Myers Squibb Co Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US20140193410A1 (en) 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US10072076B2 (en) 2013-03-14 2018-09-11 Regeneron Pharmaceuticals, Inc. Human antibodies to NAv1.7
DK2970473T3 (da) 2013-03-14 2017-11-27 Bristol Myers Squibb Co Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
BR112016005303A2 (pt) 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
WO2015061668A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
ES2769778T3 (es) 2013-12-13 2020-06-29 Swedish Stromabio Ab Composiciones inmunomoduladoras
US10407502B2 (en) 2014-01-15 2019-09-10 Kadmon Corporation, Llc Immunomodulatory agents
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX370283B (es) 2014-02-06 2019-12-09 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN106456756B (zh) 2014-05-13 2021-04-23 免疫医疗有限公司 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
ES2753360T3 (es) 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
AU2015301338C1 (en) 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
TWI790593B (zh) 2014-08-19 2023-01-21 美商默沙東有限責任公司 抗tigit抗體
RU2710354C2 (ru) 2014-08-29 2019-12-25 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе нацеленных на опухоль иммуноцитокинов, содержащих вариант il-2, и антител к человеческому pd-l1
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US20220372153A1 (en) 2015-03-03 2022-11-24 Kymab Limited Synergistic combinations of ox40l antibodies for the treatment of gvhd
LT3265123T (lt) 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
DK3273992T3 (da) 2015-03-23 2020-07-27 Jounce Therapeutics Inc Antistoffer mod ICOS
EP3277320A4 (en) 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN108290936B (zh) 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
SMT202500003T1 (it) 2015-09-25 2025-03-12 Hoffmann La Roche Anticorpi anti-tigit e procedimenti di utilizzo
WO2017059095A1 (en) 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
WO2017087547A1 (en) 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
CN108350080A (zh) 2015-11-24 2018-07-31 伊莱利利公司 用于癌症的联合疗法
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
US10118963B2 (en) 2016-01-29 2018-11-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2017148424A1 (zh) 2016-03-04 2017-09-08 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途
AU2017264683B2 (en) 2016-05-09 2024-02-29 Igm Biosciences, Inc. Anti-PD-L1 antibodies
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
WO2017213695A1 (en) 2016-06-07 2017-12-14 The Brigham And Women's Hospital, Inc. Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
US10077308B2 (en) 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
AU2017283181B2 (en) 2016-06-20 2024-08-15 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
RU2749109C2 (ru) 2016-06-29 2021-06-04 Чекпойнт Терапьютикс, Инк. Специфические антитела к pd-l1 и способы их применения
CA3030156A1 (en) 2016-07-07 2018-01-11 Iovance Biotherapeutics, Inc. Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
ES2899036T3 (es) 2016-08-04 2022-03-09 Innovent Biologics Suzhou Co Ltd Nanocuerpo anti-PD-L1 y su uso
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
JP6925421B2 (ja) 2016-08-05 2021-08-25 ワイ−バイオロジクス・インコーポレイテッド プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN116492457A (zh) 2016-09-10 2023-07-28 耶达研究与开发有限公司 降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤
IL265485B2 (en) 2016-09-20 2024-07-01 Pfizer Diagnostic anti-PD-L1 antibody and its use
KR102543323B1 (ko) 2016-10-30 2023-06-14 상하이 헨리우스 바이오테크, 인크. 항-pd-l1 항체 및 변이체
MA46708B1 (fr) 2016-11-02 2021-10-29 Jounce Therapeutics Inc Anticorps anti-pd1 et leurs utilisations
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
RU2766582C2 (ru) 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP7105238B2 (ja) 2017-01-18 2022-07-22 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体に対するイディオタイプ抗体及びそれらの使用
PL3592769T3 (pl) 2017-03-09 2024-10-14 Genmab A/S Przeciwciała przeciwko PD-L1
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EA201900443A1 (ru) 2017-04-18 2020-03-06 Р-Фарм Оверсиз Инк. Антитело к pd-l1 и его применение
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
US10442866B1 (en) 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof

Also Published As

Publication number Publication date
HRP20220891T1 (hr) 2022-10-14
ES2922734T3 (es) 2022-09-19
JP7022181B2 (ja) 2022-02-17
US9587030B2 (en) 2017-03-07
US20170327587A1 (en) 2017-11-16
IL304772B1 (en) 2025-06-01
JP7375062B2 (ja) 2023-11-07
JP2020202866A (ja) 2020-12-24
AU2020294247B2 (en) 2024-08-01
CN112048020A (zh) 2020-12-08
DE112015001085T5 (de) 2016-12-08
CN106459196A (zh) 2017-02-22
US20160368997A1 (en) 2016-12-22
WO2015132580A1 (en) 2015-09-11
NZ761537A (en) 2024-03-22
US11773175B2 (en) 2023-10-03
DK3113797T3 (da) 2022-07-25
SI3113797T1 (sl) 2022-10-28
CA2941066A1 (en) 2015-09-11
EP3113797B1 (en) 2022-05-04
IL304772B2 (en) 2025-10-01
CN112048020B (zh) 2025-07-08
US20190276547A1 (en) 2019-09-12
JP2022078042A (ja) 2022-05-24
AU2024227793A1 (en) 2024-11-21
US10654935B2 (en) 2020-05-19
JP2017513813A (ja) 2017-06-01
JP6795398B2 (ja) 2020-12-02
US11396550B2 (en) 2022-07-26
SG11201607030PA (en) 2016-09-29
US20210395378A1 (en) 2021-12-23
US20170044250A1 (en) 2017-02-16
GB201403775D0 (en) 2014-04-16
US20240132605A1 (en) 2024-04-25
US20250263492A1 (en) 2025-08-21
RS63408B1 (sr) 2022-08-31
EP3113797A1 (en) 2017-01-11
PL3113797T3 (pl) 2022-09-12
LT3113797T (lt) 2022-09-12
IL304772A (en) 2023-09-01
AU2020294246B2 (en) 2024-05-23
AU2020294246A1 (en) 2021-01-28
IL247582B1 (en) 2023-09-01
US20210087287A1 (en) 2021-03-25
US20170002083A1 (en) 2017-01-05
IL247582B2 (en) 2024-01-01
US10669342B2 (en) 2020-06-02
CN106459196B (zh) 2020-09-22
AU2015225926B2 (en) 2020-10-15
HUE059338T2 (hu) 2022-11-28
US11753479B2 (en) 2023-09-12
AU2015225926A1 (en) 2016-09-22
IL247582A0 (en) 2016-11-30
JP2024012374A (ja) 2024-01-30
PT3113797T (pt) 2022-07-11
AU2020294247A1 (en) 2021-01-28
NZ723858A (en) 2023-09-29
IL320713A (en) 2025-07-01
EP3590539A1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
US11773175B2 (en) Antibodies, uses and methods
US9139653B1 (en) Anti-human OX40L antibodies and methods of treatment
EP3265123B1 (en) Antibodies, uses & methods
US9868789B2 (en) Synergistic combinations of OX40L antibodies for the treatment of GvHD
EP3094651B1 (en) Anti-light antibodies
US9434785B1 (en) Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US20220372153A1 (en) Synergistic combinations of ox40l antibodies for the treatment of gvhd
Class et al. Patent application title: ANTIBODIES, USES & METHODS
HK40018127A (en) Antibodies, uses & methods
HK1229239B (en) Antibodies, uses&methods
HK1229239A1 (en) Antibodies, uses&methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226

EEER Examination request

Effective date: 20200226